Dr. Reddy's Laboratories Ltd (RDY) 54.15 $RDY
The Top ADRs To Buy This Week
Todd Campbell - at Seeking Alpha - Thu Feb 12, 6:40AM CST
RUK: 71.70 (-1.02), BUD: 121.72 (-0.80), ANW: 14.92 (+0.25), DEG: 21.85 (-0.05), ENL: 50.46 (-0.66), FBR: 13.05 (-0.23), SNE: 27.30 (+0.19), TM: 132.49 (+0.67), RDY: 54.15 (-0.01), LUX: 58.79 (-1.11), OMAB: 38.76 (-0.66), TTM: 48.34 (+0.42), SNN: 35.82 (-0.28), RYAAY: 61.46 (-2.33), EDAP: 3.55 (+0.13), AZN: 69.96 (+0.20), TRIB: 17.30 (-0.12), EFA: 63.82 (+0.42), WX: 41.53 (+0.45), TEVA: 56.77 (-0.58)
Dr. Reddy's (RDY) Q3 Earnings Down 7% Y/Y, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 9:50AM CST
Dr. Reddy's Laboratories (RDY) reported third-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 53 cents, down 7% from the year-ago quarter.
MNK: 115.01 (+2.51), CRIS: 3.23 (+0.25), RDY: 54.15 (-0.01), NVS: 102.20 (-0.17)
Dr. Reddy's Laboratories (RDY) Q3 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Jan 29, 7:00PM CST
RDY: 54.15 (-0.01)
Dr. Reddy's (RDY) Stock Gained Today on Earnings Beat
at The Street - Thu Jan 29, 3:54PM CST
Dr. Reddy's (RDY) shares were up today after the company reported third quarter results that beat analysts' guidance.
RDY: 54.15 (-0.01)
Dr. Reddy's ups revenues 9% in FQ3
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 10:02AM CST
RDY: 54.15 (-0.01)
Dr. Reddy's EPS of $0.53
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 4:52AM CST
RDY: 54.15 (-0.01)
Dr. Reddy's Q3 and 9 Months FY15 Financial Results
Business Wire - Thu Jan 29, 4:12AM CST
--Q3 FY15 EBITDA at Rs. 10.5 billion(27% of revenues)
RDY: 54.15 (-0.01)
3 Emerging-Market Stocks to Buy for 2015
Motley Fool Staff, Dan Dzombak, Dan Caplinger, and Todd Campbell - Motley Fool - Fri Jan 23, 5:02PM CST
Source: Flickr user GovernmentZA. Slowing growth and commodity crashes have made it a tough run for former emerging-market darlings Brazil, India, Russia, and China, but that doesn't mean there aren't companies in these emerging markets that may be...
QIHU: 60.48 (+1.47), V: 269.63 (-1.28), BIDU: 212.13 (+7.11), RDY: 54.15 (-0.01), GOOG: 549.01 (+6.08), MA: 87.14 (-0.38), YNDX: 17.00 (+0.59)
Curis (CRIS) in Focus: Stock Adds 17.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 23, 7:51AM CST
Curis, Inc. (CRIS) was a big mover last session, as its shares rose almost 18% on the day.
CRIS: 3.23 (+0.25), RDY: 54.15 (-0.01)
Curis Up on Immuno-Oncology Agreement with Aurigene - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 5:35PM CST
Curis (CRIS) inked an exclusive collaboration agreement with Aurigene Discovery Technologies Limited, an independent, wholly owned subsidiary of Dr. Reddy's Laboratories Ltd. with a focus on immuno-oncology and selected precision oncology targets.
CRIS: 3.23 (+0.25), AMGN: 153.48 (+0.30), RDY: 54.15 (-0.01)
Dr. Reddy's reports January 29
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 9:46AM CST
RDY: 54.15 (-0.01)
Dr. Reddy's to Release Q3 FY15 Results on January 29, 2015
Business Wire - Thu Jan 22, 9:31AM CST
Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Third Quarter ended December 31, 2014 on Thursday, January 29, 2015 after the Board Meeting. The results will be available on the Company's website www.drreddys.com.
RDY: 54.15 (-0.01)
Curis and Aurigene Announce Collaboration, License and Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and Precision Oncology Targets
GlobeNewswire - Wed Jan 21, 5:05AM CST
-- Agreement Provides Curis with Option to Exclusively License Aurigene's Antagonists for Immuno-Oncology, Including an Antagonist of PD-L1 and Selected Precision Oncology Targets, Including an IRAK4 Kinase Inhibitor --
CRIS: 3.23 (+0.25), RDY: 54.15 (-0.01)
Two Banks, Four ETFs Surge As India Cuts Lending Rate
at Investor's Business Daily - Thu Jan 15, 4:33PM CST
India's markets surged Thursday after a surprise interest rate cut by the nation's central bank. Bombay's benchmark Sensex index vaulted 2.7%, its biggest one-day advance since May. The Reserve Bank of India cut its lending rate to banks by 0.25% to...
INDY: 32.71 (+0.35), IBN: 11.70 (+0.06), HDB: 58.41 (-0.98), EPI: 23.89 (+0.22), MMYT: 24.55 (+0.09), INFY: 36.60 (-0.13), RDY: 54.15 (-0.01), REDF: 1.98 (+0.03), INDA: 32.95 (+0.32), SCIF: 48.37 (+0.18)
Can India Stocks Top Most World Markets This Year?
at Investor's Business Daily - Thu Jan 08, 5:29PM CST
India's stock market is still slightly underwater in the new year after a rough start, but it outperformed most of its global peers last year. The Bombay Stock Exchange's Sensex index rose nearly 30% in 2014, its biggest annual gain in the past five...
IBN: 11.70 (+0.06), HDB: 58.41 (-0.98), RDY: 54.15 (-0.01), NVS: 102.20 (-0.17), TTM: 48.34 (+0.42)
Buy Dr. Reddy Laboratories: Recent Correction Offers An Attractive Entry Point
Pharma Intelligence - at Seeking Alpha - Tue Dec 30, 7:30AM CST
RDY: 54.15 (-0.01)
Dr. Reddy's Laboratories acquires Habitrol Brand from Novartis
M2 - Fri Dec 19, 7:09AM CST
Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) reported on Thursday the completion of the acquisition of title and rights of Habitrol brand from Novartis Consumer Health under an asset purchase agreement.
RDY: 54.15 (-0.01), NVS: 102.20 (-0.17)
Dr. Reddy's Laboratories Closes the Acquisition of Habitrol(R) Brand from Novartis
Business Wire - Fri Dec 19, 1:18AM CST
Dr. Reddy's Laboratories has announced that it has closed the acquisition of Habitrol(R) brand (an over-the-counter nicotine replacement therapy transdermal patch) from Novartis Consumer Health Inc. following issuance of the proposed consent order from the U.S. Federal Trade Commission (FTC) on November 26, 2014. The company had earlier entered into an asset purchase agreement with Novartis Consumer Health Inc. to acquire the title and rights of Habitrol(R) brand and to market the product in the U.S. market.
RDY: 54.15 (-0.01), NVS: 102.20 (-0.17)
Dr. Reddy's Laboratories (RDY) in Focus: Stock Falls 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 8:06AM CST
Dr. Reddy's Laboratories stock fell over 7% last trading session, continuing its recent downtrend
AKRX: 47.28 (-0.25), RDY: 54.15 (-0.01)
Stock Futures Point Lower; Russia, India Stocks Pressured
at Investor's Business Daily - Tue Dec 16, 8:20AM CST
Stock futures were moderately lower ahead of Tuesday's open, despite volatile overseas stock and currency trading. Dow futures were 29.8 points below fair market value and off their early lows. Nasdaq 100 futures were under some serious pressure,...
TLM: 7.63 (-0.03), RUSS: 11.59 (-0.81), RDY: 54.15 (-0.01), NUGT: 15.78 (+0.22), IBN: 11.70 (+0.06), JNUG: 30.90 (+1.14), HDB: 58.41 (-0.98), RSX: 18.05 (+0.39), YNDX: 17.00 (+0.59)
The Top ADRs To Buy This Week
Todd Campbell - at Seeking Alpha - Thu Feb 12, 6:40AM CST
RUK: 71.70 (-1.02), BUD: 121.72 (-0.80), ANW: 14.92 (+0.25), DEG: 21.85 (-0.05), ENL: 50.46 (-0.66), FBR: 13.05 (-0.23), SNE: 27.30 (+0.19), TM: 132.49 (+0.67), RDY: 54.15 (-0.01), LUX: 58.79 (-1.11), OMAB: 38.76 (-0.66), TTM: 48.34 (+0.42), SNN: 35.82 (-0.28), RYAAY: 61.46 (-2.33), EDAP: 3.55 (+0.13), AZN: 69.96 (+0.20), TRIB: 17.30 (-0.12), EFA: 63.82 (+0.42), WX: 41.53 (+0.45), TEVA: 56.77 (-0.58)
Dr. Reddy's (RDY) Q3 Earnings Down 7% Y/Y, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 9:50AM CST
Dr. Reddy's Laboratories (RDY) reported third-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 53 cents, down 7% from the year-ago quarter.
MNK: 115.01 (+2.51), CRIS: 3.23 (+0.25), RDY: 54.15 (-0.01), NVS: 102.20 (-0.17)
Dr. Reddy's Laboratories (RDY) Q3 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Jan 29, 7:00PM CST
RDY: 54.15 (-0.01)
Dr. Reddy's (RDY) Stock Gained Today on Earnings Beat
at The Street - Thu Jan 29, 3:54PM CST
Dr. Reddy's (RDY) shares were up today after the company reported third quarter results that beat analysts' guidance.
RDY: 54.15 (-0.01)
Dr. Reddy's ups revenues 9% in FQ3
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 10:02AM CST
RDY: 54.15 (-0.01)
Dr. Reddy's EPS of $0.53
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 4:52AM CST
RDY: 54.15 (-0.01)
Dr. Reddy's Q3 and 9 Months FY15 Financial Results
Business Wire - Thu Jan 29, 4:12AM CST
--Q3 FY15 EBITDA at Rs. 10.5 billion(27% of revenues)
RDY: 54.15 (-0.01)
3 Emerging-Market Stocks to Buy for 2015
Motley Fool Staff, Dan Dzombak, Dan Caplinger, and Todd Campbell - Motley Fool - Fri Jan 23, 5:02PM CST
Source: Flickr user GovernmentZA. Slowing growth and commodity crashes have made it a tough run for former emerging-market darlings Brazil, India, Russia, and China, but that doesn't mean there aren't companies in these emerging markets that may be...
QIHU: 60.48 (+1.47), V: 269.63 (-1.28), BIDU: 212.13 (+7.11), RDY: 54.15 (-0.01), GOOG: 549.01 (+6.08), MA: 87.14 (-0.38), YNDX: 17.00 (+0.59)
Curis (CRIS) in Focus: Stock Adds 17.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 23, 7:51AM CST
Curis, Inc. (CRIS) was a big mover last session, as its shares rose almost 18% on the day.
CRIS: 3.23 (+0.25), RDY: 54.15 (-0.01)
Curis Up on Immuno-Oncology Agreement with Aurigene - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 5:35PM CST
Curis (CRIS) inked an exclusive collaboration agreement with Aurigene Discovery Technologies Limited, an independent, wholly owned subsidiary of Dr. Reddy's Laboratories Ltd. with a focus on immuno-oncology and selected precision oncology targets.
CRIS: 3.23 (+0.25), AMGN: 153.48 (+0.30), RDY: 54.15 (-0.01)
Dr. Reddy's reports January 29
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 9:46AM CST
RDY: 54.15 (-0.01)
Dr. Reddy's to Release Q3 FY15 Results on January 29, 2015
Business Wire - Thu Jan 22, 9:31AM CST
Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Third Quarter ended December 31, 2014 on Thursday, January 29, 2015 after the Board Meeting. The results will be available on the Company's website www.drreddys.com.
RDY: 54.15 (-0.01)
Curis and Aurigene Announce Collaboration, License and Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and Precision Oncology Targets
GlobeNewswire - Wed Jan 21, 5:05AM CST
-- Agreement Provides Curis with Option to Exclusively License Aurigene's Antagonists for Immuno-Oncology, Including an Antagonist of PD-L1 and Selected Precision Oncology Targets, Including an IRAK4 Kinase Inhibitor --
CRIS: 3.23 (+0.25), RDY: 54.15 (-0.01)
Two Banks, Four ETFs Surge As India Cuts Lending Rate
at Investor's Business Daily - Thu Jan 15, 4:33PM CST
India's markets surged Thursday after a surprise interest rate cut by the nation's central bank. Bombay's benchmark Sensex index vaulted 2.7%, its biggest one-day advance since May. The Reserve Bank of India cut its lending rate to banks by 0.25% to...
INDY: 32.71 (+0.35), IBN: 11.70 (+0.06), HDB: 58.41 (-0.98), EPI: 23.89 (+0.22), MMYT: 24.55 (+0.09), INFY: 36.60 (-0.13), RDY: 54.15 (-0.01), REDF: 1.98 (+0.03), INDA: 32.95 (+0.32), SCIF: 48.37 (+0.18)
Can India Stocks Top Most World Markets This Year?
at Investor's Business Daily - Thu Jan 08, 5:29PM CST
India's stock market is still slightly underwater in the new year after a rough start, but it outperformed most of its global peers last year. The Bombay Stock Exchange's Sensex index rose nearly 30% in 2014, its biggest annual gain in the past five...
IBN: 11.70 (+0.06), HDB: 58.41 (-0.98), RDY: 54.15 (-0.01), NVS: 102.20 (-0.17), TTM: 48.34 (+0.42)
Buy Dr. Reddy Laboratories: Recent Correction Offers An Attractive Entry Point
Pharma Intelligence - at Seeking Alpha - Tue Dec 30, 7:30AM CST
RDY: 54.15 (-0.01)
Dr. Reddy's Laboratories acquires Habitrol Brand from Novartis
M2 - Fri Dec 19, 7:09AM CST
Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) reported on Thursday the completion of the acquisition of title and rights of Habitrol brand from Novartis Consumer Health under an asset purchase agreement.
RDY: 54.15 (-0.01), NVS: 102.20 (-0.17)
Dr. Reddy's Laboratories Closes the Acquisition of Habitrol(R) Brand from Novartis
Business Wire - Fri Dec 19, 1:18AM CST
Dr. Reddy's Laboratories has announced that it has closed the acquisition of Habitrol(R) brand (an over-the-counter nicotine replacement therapy transdermal patch) from Novartis Consumer Health Inc. following issuance of the proposed consent order from the U.S. Federal Trade Commission (FTC) on November 26, 2014. The company had earlier entered into an asset purchase agreement with Novartis Consumer Health Inc. to acquire the title and rights of Habitrol(R) brand and to market the product in the U.S. market.
RDY: 54.15 (-0.01), NVS: 102.20 (-0.17)
Dr. Reddy's Laboratories (RDY) in Focus: Stock Falls 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 8:06AM CST
Dr. Reddy's Laboratories stock fell over 7% last trading session, continuing its recent downtrend
AKRX: 47.28 (-0.25), RDY: 54.15 (-0.01)
Stock Futures Point Lower; Russia, India Stocks Pressured
at Investor's Business Daily - Tue Dec 16, 8:20AM CST
Stock futures were moderately lower ahead of Tuesday's open, despite volatile overseas stock and currency trading. Dow futures were 29.8 points below fair market value and off their early lows. Nasdaq 100 futures were under some serious pressure,...
TLM: 7.63 (-0.03), RUSS: 11.59 (-0.81), RDY: 54.15 (-0.01), NUGT: 15.78 (+0.22), IBN: 11.70 (+0.06), JNUG: 30.90 (+1.14), HDB: 58.41 (-0.98), RSX: 18.05 (+0.39), YNDX: 17.00 (+0.59)
